Trefoil Factor 3 Human ELISA

Regulatery Status: RUO
Type: Sandwich ELISA, Biotin-labelled antibody
Other Names Status: TFF3, Intestinal trefoil factor, P1.B, ITF, Polypeptide P1.B, TFI
Species: Human
Catalog No Size
Product Catalog No: RD191160200R Pack Size: 96 wells (1 kit)

Pack Size:
Pack Size:
Pack Size:
Pack Size:

Category:
Product Features

Trefoil factor 3 (TFF3, also known as intestinal trefoil factor) belongs together with TFF1 and TFF2 to a small group of mucin-associated peptides. TFF3 contains seven cysteine residues, six of which form disulfide bonds to create a characteristic three-leafed structure. Due to its compact structure, TFF3 is extremely resistant toward acids, proteolytical cleavage or heat degradation. Monomeric form of TFF3 consists of 60 amino acids and has 6.7 kDa, while the dimer (13.1 kDa) consists of 118 amino acids. TFF3 is expressed mainly in gastrointestinal tract, in the mucous cells of the small and large intestine, where it maintains the integrity of mucous layer and in cooperation with mucins protects the gastrointestinal epithelial cells against various injurious agents. However, TFF3 was also detected in salivary glands, posterior pituitary gland and in the inner ear. Secretion of TFF3 is triggered by the presence of certain inflammation mediators and neurotransmitters. Studies showed that oral administration of TFF3 in rats protects gastric mucosa from damage. Over-expression of TFF3 occurs at the sites of damage of the gastrointestinal tract, e.g. peptic ulcer or inflammatory bowel disease. Patients suffering from these diseases have increased levels of TFF3 in serum. TFF3 was reported to be over-expressed also in patients with various neoplasms including intestinal, pancreatic and prostate carcinomas. On the contrary, its expression decreases in thyroid follicular carcinomas. In vitro studies showed that in breast cancer cells, expression of TFF3 is regulated by the level of estrogen. Recent study with human and rodent pancreatic islet β-cells has demonstrated that TFF3 overexpression increases their proliferation. Both major forms of diabetes involve a decline in islet β-cells mass and their controlled expansion would have great potential utility for treatment of this diseases. Another study with rats has shown that urinary TFF3 protein levels were markedly reduced in response to renal tubular injury, while his levels did not respond to nonrenal toxicants.

Technical Sheet / Info

Intended use

The RD191160200R Human Trefoil Factor 3 ELISA is a sandwich enzyme immunoassay for the quantitative measurement of human total trefoil factor 3 protein (TFF3).

  • It is intended for research use only
  • The total assay time is less than 3.5 hours
  • The kit measures total TFF3 in serum, plasma (EDTA, citrate, heparin), BALF, and urine samples
  • Special Dilution Buffer (Cat. No.: C005114) needed for the dilution of urine and BALF samples is not included and can be obtained from BioVendor.
  • Assay format is 96 wells
  • Quality Controls are human serum based
  • Standard is recombinant protein based
  • Components of the kit are provided ready to use, concentrated or lyophilized

Clinical Application

  • Neoplasmas
  • Carcinomas
  • Diabetes mellitus
  • Kidney tubular injury

Test principle

In the BioVendor Human Trefoil Factor 3 ELISA, standards, quality controls and samples are incubated in microplate wells precoated with polyclonal anti-human TFF3 antibody. After 60 minutes incubation and washing, biotin labelled polyclonal anti-human TFF3 antibody is added and incubated with captured TFF3 for 60 minutes. After another washing, streptavidin-HRP conjugate is added. After 30 minutes incubation and the last washing step, the remaining conjugate is allowed to react with the substrate solution (TMB). The reaction is stopped by addition of acidic solution and absorbance of the resulting yellow product is measured. The absorbance is proportional to the concentration of TFF3. A standard curve is constructed by plotting absorbance values against concentrations of standards, and concentrations of unknown samples are determined using this standard curve.

Summary of protocol

  • Reconstitute QCs and Master Standard and prepare set of standards
  • Dilute samples 5×
  • Add 100 μl Standards, QCs and samples
  • Incubate at RT for 1 hour/300 rpm
  • Wash plate 3 times
  • Add 100 μl Biotin Labelled Antibody
  • Incubate at RT for 1 hour/300 rpm
  • Wash plate 3 times
  • Add 100 μl Streptavidin-HRP Conjugate
  • Incubate at RT for 30 min/300 rpm
  • Wash plate 3 times
  • Add 100 μl Substrate Solution
  • Incubate at RT for 10 min
  • Add 100 μl Stop Solution
  • Read absorbance and calculate results

Order Enquiry

    Order Enquiry Form

    References

    – Henze D, Doecke WD, Hornung D, Agueusop I, von Ahsen O, Machens K, Schmitz AA, Gashaw I. Endometriosis Leads to an Increased Trefoil Factor 3 Concentration in the Peritoneal Cavity but Does Not Alter Systemic Levels. Reprod Sci. 2016 Jun 20;

    – Samson MH, Nexo E. Validation of commercial assays for measurements of trefoil factor family peptides in serum. Clin Chem Lab Med. 2011 Dec;49 (12):2057-60

    Enquiry